Evidence map›Paper›PMID 40022717›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2025

Frequency of JAK2V617F Mutation Zygosity and Impact on Disease Outcome in MPN Patients.

Mushtaq M Khazeem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Role of JAK2 V617F in Myeloproliferative Neoplasms: From Mutation to Manifestation: A Review.Nigerian medical journal : journal of the Nigeria Medical Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mushtaq M KhazeemDepartment of Molecular Biology, The National Center of Hematology, Mustansiriyah University, Baghdad 10015, Iraq.ORCID 0000-0003-2948-8225

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyeloproliferative Neoplasm (MPN) is a clonal disorder of blood progenitor cells during haematopoiesis. JAK2V617F mutation represents one of the major identified genetic reasons of MPN disorder. It has been shown that JAK2V617F zygosity is associated with disease phenotype. However, studies showed variable findings regarding individual phenotype parameters and significance of effect.

objectivesthe aim of this study was to determine frequency of JAK2V617F zygosity and corresponding outcomes in this population.

methodsThis cross-section study recruited JAK2V617F-mutated polycythemia Vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) patients. DNA samples were extracted from peripheral blood and JAK2V617F zygosity was determined using ARMS-PCR method.

resultsA total of 162 patients (91 males and 71 females) were analysed. Of total, 131 (80.86 %) were heterozygous and 31 (19.14 %) were homozygous for JAK2V617F. homozygous characterized with higher age (P= 0.0153) and WBC count (P= < 0.0001). Among total MPN cases, the number of PV, ET, and MF patients was 102 (62.96%), 37 (22.84%), and 23 (14.2%) respectively. The frequency of homozygous cases was 20.6 %, 10.8 %, and 26.1 % for PV, ET, and MF patients respectively. No significant difference seen in age, BMI, and HCT between homozygous and heterozygous cases in all MPN groups. In ET group, homozygous patients showed significant HGB reduction (P= 0.0186) and PLT increase (P= 0.0034) compared with heterozygous patients. WBC count in homozygous patients was significantly higher than heterozygous in PV (P= 0.0071), ET (P= <0.0001), and MF (P= 0.07) patients.

conclusionJAK2V617F zygosity is useful marker in determining disease severity and can be used for prediction of prognosis in MPN patients. ARMS-PCR is simple, easy, and useful technique in determining zygosity of mutations and does not need to advanced laboratory resources. We recommend including zygosity in laboratory reports when conducting JAK2V617F using ARMS-PCR technique.

Indexed as

Janus Kinase 2MutationMyeloproliferative DisordersPolycythemia VeraThrombocythemia, EssentialAdultAgedAged, 80 and overCross-Sectional StudiesFemaleFollow-Up StudiesHomozygoteHumansMaleMiddle AgedPrognosisJAK2 protein, humanJanus Kinase 2allele burdenARMS-PCRJAK2V617FMPNzygosity

Identifiers

PMID40022717
PMCPMC12118020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.